Does Ketoconazole Shampoo Help With Hair Loss, or Just Dandruff?
Published by AmpleLab Research
Ketoconazole shampoo is licensed primarily for dandruff and seborrhoeic dermatitis, a scalp condition linked to an overgrowth of the yeast Malassezia. It's also one of the most recommended shampoo add-ons in hair loss communities, usually alongside minoxidil or finasteride. Those two facts sit oddly together, and the confusion isn't helped by how often it gets framed as a rival to prescription treatments, something to compare head-to-head with finasteride or minoxidil, when the actual evidence never really tested it that way.
This article covers what ketoconazole shampoo is actually licensed for, the mechanism proposed for its effect on androgenetic alopecia (AGA), and what the human evidence shows, including a correction to a specific trial detail that gets misreported constantly across hair loss content, this article included until we checked it directly against the source.
What It's Actually Licensed For
Ketoconazole is an imidazole antifungal used in various forms for various fungal conditions. The shampoo formulation specifically is licensed, in the UK and elsewhere, for dandruff and seborrhoeic dermatitis, conditions strongly associated with Malassezia yeast overgrowth on the scalp. These shampoos (typically 1-2%) are widely available in UK pharmacies without a prescription for this use, usually with a brief consultation for the stronger 2% strength. Any use for androgenetic alopecia is off-label: it's not what the shampoo is approved to treat, even though it's what a large share of the people buying it are actually using it for.
That off-label status doesn't mean the AGA use is baseless, ketoconazole has a genuine, mechanistically plausible role in hair loss that's separate from its antifungal action. But it does mean the evidence base is smaller, older, and less rigorously trialled than the evidence behind minoxidil or finasteride, and it's worth being upfront about that difference in evidence quality before getting into the mechanism.
The Proposed Mechanism in AGA
Two main mechanisms have been proposed for why ketoconazole might affect AGA beyond its antifungal action: possible local anti-androgen activity at the scalp, and effects on the inflammatory environment around the follicle. Our article on DHT and the androgen pathway covers the receptor biology these mechanisms are interacting with in more depth.
This study ran a laboratory assay using CV-1 cells transfected with androgen receptors, testing whether ketoconazole interfered with androgen receptor transactivation. It did, supporting a genuine anti-androgen mechanism at the receptor level. The same paper also reported two case photographs of Japanese men using topical ketoconazole, with hair regrowth reported that reversed on stopping and resumed on restarting. That's a laboratory finding plus an anecdotal case observation, not a controlled clinical trial, and should be weighted accordingly.
Separately, an animal study clipped the coat hair of C3H/HeN mice and applied either a 2% ketoconazole solution or a vehicle solution once daily for three weeks, finding significantly greater regrowth in the treated group (p<0.01). Because this was a mouse hair-cycle model rather than a human AGA study, it establishes biological activity rather than clinical efficacy in human pattern hair loss.
Neither of these findings establishes that ketoconazole meaningfully suppresses DHT the way finasteride does, and no study has claimed that. Ketoconazole's proposed AGA mechanisms are local and less thoroughly characterised, alongside an anti-inflammatory action that isn't hormonal at all. That distinction matters for how it should be positioned relative to prescription treatments, covered further down.
What the Human Evidence Shows
The human evidence for ketoconazole in AGA rests on two studies from the late 1990s and early 2000s, both small by modern standards, plus a 2020 systematic review that pulled the evidence base together.
This trial compared 2% ketoconazole shampoo against an unmedicated shampoo, used with or without 2% topical minoxidil. Hair density and the proportion of follicles in the anagen (growth) phase improved to a broadly similar degree in the ketoconazole and minoxidil groups; the authors themselves note further controlled studies were needed. This is a genuinely useful comparison point, the observed improvements were broadly similar to those seen with 2% topical minoxidil, a lower-strength formulation than the 5% products commonly used today, but it says nothing about how it compares to finasteride, and the trial predates most modern reporting standards for dermatology RCTs.
The second study is the one worth being precise about, because it's widely misreported. A number of hair loss articles describe a trial of 150 men split into four groups, including a ketoconazole-only arm, with specific before-and-after hair cycle numbers attached. We checked this directly against the original paper, and that description doesn't match it.
This was a 100-man, four-group open trial, not 150 men, and there was no ketoconazole-only arm. The groups were: oral finasteride alone (30 patients), finasteride with topical 2% minoxidil (36 patients), 2% minoxidil alone (24 patients), and finasteride with 2% ketoconazole shampoo (10 patients). Patients were assessed every three months for a year. Hair growth was observed in all groups, with the finasteride-plus-minoxidil group performing best, closely followed by the finasteride-plus-ketoconazole group, with no significant difference reported between those two. Both outperformed finasteride alone and minoxidil alone. No significant side effects were reported.
That's a real and interesting finding, adding ketoconazole to finasteride performed on par with adding minoxidil to finasteride in this trial. But the ketoconazole-containing arm had only 10 patients, which is a small subgroup within an already modest trial, and there was no ketoconazole-alone comparison at all. It tells us something about ketoconazole as an add-on to finasteride specifically, not about what it does by itself.
This systematic review searched for all available evidence on topical ketoconazole in AGA and identified just seven eligible papers: two animal studies and five human studies, with a combined 318 human participants across all five. That's the entire evidence base, spread thin across studies with different designs, doses, and outcome measures. The review's conclusion was that ketoconazole shows promise as an adjunctive or alternative therapy, language that itself reflects how preliminary the evidence still is.
Why "Ketoconazole vs Finasteride" Isn't the Right Comparison
No study covered above pitted ketoconazole against finasteride as competing standalone treatments, and the mechanisms explain why that comparison doesn't really make sense. Finasteride works systemically, inhibiting type II 5-alpha reductase and meaningfully reducing DHT throughout the body. Ketoconazole's proposed AGA mechanisms are local and less thoroughly characterised, alongside an anti-inflammatory action that isn't hormonal at all. These are different categories of intervention, not two versions of the same one.
The trial evidence that does exist, Piérard-Franchimont's comparison to minoxidil, and Khandpur's finasteride-plus-ketoconazole arm performing on par with finasteride-plus-minoxidil, consistently positions ketoconazole as something used alongside a primary treatment, not instead of one. Every current review of the evidence, including the 2025 update covered below, frames it the same way: adjunctive, not a substitute for finasteride, minoxidil, or topical anti-androgens.
Practical Use and Where It Fits
Where ketoconazole shampoo is used for AGA off-label, the trials above generally applied it two to three times a week, left on the scalp for a few minutes before rinsing, similar to its licensed dandruff dosing. It's a wash-off product used briefly at the shampoo step, distinct from leave-on scalp treatments applied to dry skin. Worth noting separately: scalp inflammation and Malassezia overgrowth can themselves contribute to a shedding pattern that's sometimes confused with androgenetic thinning, so someone whose shedding is actually driven by scalp inflammation may see a real improvement from ketoconazole that has nothing to do with its proposed AGA mechanism at all. Our article on telogen effluvium vs androgenetic alopecia covers how to tell the two apart.
Because it works at a different point in a routine, wash-off rather than leave-on, it doesn't conflict with actives like 1% AHK-Cu Hair and Scalp Serum or 2% 2dDR Hair Serum, both formulated as leave-on scalp products rather than wash-off shampoos. Someone genuinely dealing with dandruff or seborrhoeic dermatitis alongside pattern hair loss has a reasonable case for using ketoconazole shampoo for the scalp condition it's actually licensed for, with any AGA benefit as a secondary consideration rather than the primary reason to reach for it. For DHT-focused approaches specifically, our minoxidil article, our comparison of finasteride and dutasteride, and our guide to building a combined protocol around a 5-alpha reductase inhibitor cover the treatments with the larger, more direct evidence base.
Frequently Asked Questions
Can ketoconazole shampoo replace finasteride or minoxidil?
No study has tested it as a standalone replacement for either, and nothing in the evidence base supports using it that way. It has only been studied as an addition to another treatment, or compared against topical minoxidil specifically, not against finasteride or as a solo AGA treatment in its own right.
Is ketoconazole shampoo available over the counter in the UK?
Yes, for its licensed use in dandruff and seborrhoeic dermatitis, generally available through UK pharmacies without a formal prescription, sometimes with a brief pharmacist consultation for the 2% strength. Using it for hair loss specifically is off-label, which doesn't affect its availability but does mean it isn't approved or monitored for that purpose.
Does ketoconazole reduce DHT the way finasteride does?
No. The proposed mechanism is local androgen receptor interference at the scalp, shown in a laboratory assay, not a systemic reduction in DHT production. Finasteride inhibits the enzyme that produces DHT throughout the body. These are different mechanisms operating at a different scale, not two versions of the same effect.
Who is ketoconazole shampoo actually worth trying for?
Anyone with diagnosed dandruff or seborrhoeic dermatitis alongside hair thinning has the clearest, best-supported reason to use it, treating the licensed condition directly. As an add-on for AGA specifically, the evidence is real but limited to a handful of small, older studies, so it's reasonable to view it as a supplementary option alongside a primary treatment rather than a treatment to build a routine around.
Selected Research
This article is provided for educational purposes and does not constitute medical advice. Ketoconazole shampoo is licensed for dandruff and seborrhoeic dermatitis; use for hair loss is off-label and should be discussed with a GP or dermatologist, particularly alongside prescription treatments. AmpleLab products are cosmetic formulations and are not intended to diagnose, treat, cure, or prevent any condition.
AmpleLab.